Fig. 2

Change in serum HexNAc and N-glycan branching with oral GlcNAc therapy. A–H Averaged serum HexNAc levels (A–D) or change in L-PHA binding to CD4⁺CD25⁺ T cell blasts by flow cytometry (E–H) assessed before (visits 1–4), during (visits 5–8), and after (visits 9–11) GlcNAc treatment individually (A, B, E, F) or combined (C, D, G, H). Change in L-PHA MFI is relative to baseline (V1–4). Error bars are SEM. P values by one-tailed Wilcoxin paired test (A–D) or linear mixed models (E–H) using all subjects who completed the study